Skip to main content

Advertisement

Reports to the UK Yellow Card Scheme 2000-2009 for medications used in paediatric rheumatology

Article metrics

Background & aims

The Medicines and Healthcare Regulatory Authority (MHRA) in the UK runs a national spontaneous reporting system (Yellow Card Scheme) to collect ‘suspected’ Adverse Drug Reactions (ADRs) for all medicines. To increase the data for paediatric medicines, current MHRA advice is to report all suspected ADRs in paediatric patients. Yellow Cards submitted between 2000 and 2009 were analysed for medications commonly used in paediatric rheumatology.

Methods

Data on all UK spontaneous ‘suspected’ ADRs reported to the MHRA in patients <17 years from the years 2000-9 were supplied. Data included age, type of reaction, medication and type of reporter, but were unlinked. Data were only supplied on an individual drug if five or more suspected ADRs were reported in a calendar year. The cut-off values in the data supplied were in accordance with policy guidelines applied by the MHRA to preserve confidentiality of reporters and patients.

Results

The number of reports of suspected ADRs to drugs commonly used in paediatric rheumatology per year are shown in Table 1. Adalimumab, tocilzumab & abatacept did not generate sufficient reports to feature in the dataset. There has been an increase in reporting over the 10 year period, with a median of 17 (2000-2) increasing to a median of 148 (2007-9). This increase is greater than the overall increase in reporting seen in the period (Hawcutt et al, submitted). However, the unlinked nature of the data supplied means that it is not possible to ascertain if the medications were prescribed in paediatric rheumatology patients.

Table 1 Table 1

Conclusions

Medications commonly used in paediatric rheumatology generate suspected ADR reports in the UK. The overall reporting rate appears to be increasing, but reporting of biologics is lower than expected

Author information

Correspondence to Daniel B Hawcutt.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Keywords

  • Adalimumab
  • Reporting Rate
  • Abatacept
  • Spontaneous Reporting
  • Paediatric Rheumatology